• darkblurbg

    Developing precision therapies

    for type 1 diabetes

  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®

Clinical Project Associate, GCP Quality Specialist and Office Assistant

We welcome candidates with relevant experience to join our entrepreneurial and collaborative team.

We are proud that Diamyd Medical is at the forefront of the biotech industry with the first ever precision medicine Phase 3 trial in Type 1 Diabetes.

Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly Report 2 21/22

Company Presentation

 April 4, 2022

Calendar

 Dates for financial information and other events
May 19, 2022
Erik Penser Banks Bolagsdag
vd Ulf Hannelius presenterar på Erik Penser Banks Bolagsdag. Presentationen sänds live kl. 09:35 CET.
June 3 − June 7, 2022
ADA 82nd Scientific Sessions
June 13 − June 16, 2022
BIO2022
June 22, 2022
Quarterly Report III
Quarterly Report 3 2021/2022
October 5, 2022
Year-End Report
Year-End Report 2021/2022

THE COMPANY

Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)


Read More

Order GAD for preclinical research

GAD PRODUCTS